

CHANGE IN AMINOGLYCOSIDE PHARMACOKINETICS IN CYSTIC FIBROSIS PATIENTS PRE AND POST LUNG TRANSPLANTATION, Paul Beringer, Kevin

Forrester, Jiwon Kim,
Pharmacy Practice Residency
(General Clinical Practice),
USC School of Pharmacy, Los
Angeles, California.

Cystic fibrosis patients require higher than normal doses of aminoglycosides for pseudomonal infections. Observations have been made that clearance of aminoglycosides decrease markedly in these patients post lung transplant and they require lower doses than before the transplant. The



objective of this study is to compare pharmacokinetic parameters of aminoglycoside before and after lung transplant in cystic fibrosis patients and formulate a model for aminoglycoside dosing in these patients post lung transplantation.

The method of this study is a retrospective analysis of medical records and aminoglycoside monitoring forms for all cystic fibrosis transplant patients from 1993 to present at USC University Hospital. Aminoglycoside dosage, peak and trough levels, serum creatinine, and calculated pharmacokinetic parameters are compared between pre and post lung transplant. Pre and post aminoglycoside pharmacokinetic parameters of 13 patients are compared and significant differences in renal function and pharmacokinetic profile are found. The results will be discussed and other data will be presented.